CNS Pharmaceuticals (NASDAQ: CNSP),ย a biopharmaceutical company developing treatments for primary and metastatic cancers of the brain and central nervous system, reported a leadership transition under which John Climaco has stepped down as chief executive officer and Rami Levin, MBA, has been appointed president and chief executive officer, effective Jan. 1, 2026. Levin bringsย nearly threeย decades of global leadership experience across oncology,ย neurologyย and rare diseases, withย a track recordย of advancing late-stage clinical programs, scaling organizations and leading strategic turnarounds, positioning CNS to advance its pipeline and next phase of development.
To view the full press release, visitย https://ibn.fm/FBByV
About CNSย Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.
The Companyโs drug candidate TPI 287 is anย abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. Theย initialย clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date TPI 287 appearsย haveย both an excellent safety profile and high tolerability among patients.
NOTE TO INVESTORS:โฏThe latest news and updates relating to CNSP are available in the companyโs newsroom atโฏhttps://ibn.fm/CNSP
About MissionIR
MissionIRย (โMIRโ) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands withinย theย Dynamic Brand Portfolioย @ย IBNย that delivers:ย (1) access to a vast network of wire solutions viaย InvestorWireย to efficiently and effectively reach a myriad of target markets, demographics and diverse industries;ย (2) article andย editorial syndication to 5,000+ outlets;ย (3) enhancedย press release enhancementย to ensure maximum impact;ย (4)ย social media distributionย via IBN to millions of social media followers;ย and (5) a full array of tailoredย corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in todayโs market, MIR brings its clients unparalleled recognition and brand awareness.
MIR is where breaking news, insightful content and actionable information converge.
For more information, please visitย www.MissionIR.com
Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published:ย https://www.MissionIR.com/Disclaimer
MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
Editor@MissionIR.com
MissionIR is powered byย IBN
